Loading...
Loading...
XTLB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 175.0K |
| Operating I/L | -175.0K |
| Other Income/Expense | 660.0K |
| Interest Income | 10.0K |
| Pretax | 485.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | 485.0K |
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company specializing in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate, hCDR1, is a Phase II-ready asset targeting systemic lupus erythematosus and Sjogren's syndrome. The company generates revenue through the research, development, and commercialization of hCDR1 for various indications, facilitated by its licensing agreement with Yeda Research and Development Company Limited. XTL Biopharmaceuticals Ltd. is committed to advancing innovative treatments for autoimmune diseases, driving its business through the development and potential commercialization of therapeutic solutions.
